Roivant Sciences Ltd. (NASDAQ:ROIV) finished Thursday with an addition of $0.11 to close at $11.39, an upside of 0.98 percent. An average of 3,050,580 shares of common stock have been traded in the last five days. There was a fall of -$0.11 in the past week, and it reached a new high 41 times over the past 12 months. The last 20 days have seen an average of 3,585,280 shares traded, while the 50-day average volume stands at 5,374,218.
ROIV stock has decreased by -0.26% in the last month. The company shares reached their 1-month lowest point of $10.56 on 07/24/23. With the stock rallying to its 52-week high on 07/18/23, shares of the company touched a low of $2.87 and a high of $12.01 in 52 weeks. It has reached a new high 13 times so far this year and achieved 42.55% or $3.40 in price. In spite of this, the price is down -5.12% from the 52-week high.
Insider Transactions
ROIV stock investors should be aware that Roivant Sciences Ltd. (ROIV) stock had its last reported insider trading activity 8 days ago on Aug 03. In this transaction, the insider spent $532,424. Chief Accounting Officer, Kumar Rakhi, disposed of 3,681 shares at a price of $12.00 on Aug 03. The insider now owns more than $44,172 worth of shares. Prior to that, Chief Operating Officer Venker Eric went on to Sale 16,397 shares at $11.86 each on Aug 02. An amount of $194,468 was transacted.
Valuation Metrics
Roivant Sciences Ltd. (ROIV) stock’s beta is 1.29. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 141.66, the price-to-book (PB) ratio at 7.03.
Financial Health
The quick ratio of Roivant Sciences Ltd. for the three months ended March 30 was 6.60, and the current ratio was 6.60, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.32 and a total debt to equity ratio of 0.36 for the quarter ending March 30. Its gross profit as reported stood at $48.15 million compared to revenue of $61.28 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Roivant Sciences Ltd.’s return on assets was -42.90%.
Earnings Surprise
For the three-month period that ended March 30, Roivant Sciences Ltd. had $375.52 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$33.62 million in the quarter, while revenues were shrunk -947.74%. The analyst consensus anticipated Roivant Sciences Ltd.’s latest quarter earnings to come in at -$0.36 per share, but it turned out to be -$0.2, a 44.40% surprise. For the quarter, EBITDA amounted to -$228.21 million. Shareholders own equity worth $766.81 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Roivant Sciences Ltd. (ROIV) price momentum. RSI 9-day as of the close on 10 August was 51.94%, suggesting the stock is Neutral, with historical volatility in this time frame at 48.49%.
As of today, ROIV’s price is $11.38 -0.96% or -$0.11 from its 5-day moving average. ROIV is currently trading -1.81% lower than its 20-day SMA and +30.92% higher than its 100-day SMA. However, the stock’s current price level is +25.58% above the SMA50 and +156.53% above the SMA200.
The stochastic %K and %D were 54.94% and 54.99%, respectively, and the average true range (ATR) was 0.41. With the 14-day stochastic at 57.49% and the average true range at 0.44, the RSI (14) stands at 54.59%. The stock has reached -0.21 on the 9-day MACD Oscillator while the 14-day reading was at 0.00.
Analyst Ratings
BofA Securities launched coverage on Roivant Sciences Ltd. (NASDAQ: ROIV) in its analyst report released on June 08, 2023. The firm assigned the stock a Neutral rating. The consensus rating for Roivant Sciences Ltd. (ROIV) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ROIV, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 7 others rate it as a “buy”.
What is ROIV’s price target for the next 12 months?
Analysts predict a range of price targets between $11.00 and $23.00, with a median target of $15.00. Taking a look at these predictions, the average price target given by analysts for Roivant Sciences Ltd. (ROIV) stock is $15.75.
